Nautilus Biotechnology reports Q3 2026 financial results
Nautilus reported a Q3 revenue of $0.2 million and net loss of $15.6 million. The company announced a $6 million grant to study Alzheimer's disease and its instrument availability is slated for mid-2027.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed